Baishali Nair, MD
Nephrology · Las Vegas, NVNPI 1972586600
Payments from drug & device makers
Across 579 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Fresenius USA Marketing, Inc.$1K
- Amgen$1K
- Vifor Pharma, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$958
- Bayer$699
- plus $5K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 73 | $1,913 |
| Fresenius USA Marketing, Inc. | 87 | $1,198 |
| Amgen(2 entities) | 35 | $1,040 |
| Vifor Pharma, Inc. | 71 | $1,035 |
| Otsuka America Pharmaceutical, Inc. | 63 | $958 |
| Bayer | 26 | $699 |
| Aurinia Pharma U.S., Inc. | 13 | $578 |
| Novartis | 29 | $477 |
| Calliditas Therapeutics US Inc. | 18 | $455 |
| GSK | 26 | $455 |
| Travere Therapeutics, Inc. | 17 | $450 |
| OPKO Pharmaceuticals, LLC | 22 | $418 |
| Boehringer Ingelheim | 15 | $362 |
| Novo Nordisk | 17 | $339 |
| Daiichi Sankyo Inc. | 14 | $199 |
| ANI Pharmaceuticals, Inc. | 7 | $181 |
| Nxstage Medical, Inc. | 4 | $173 |
| Mallinckrodt Hospital Products Inc. | 7 | $162 |
| Ardelyx, Inc. | 7 | $152 |
| Sanofi-aventis U.S. LLC | 1 | $122 |
| Lilly USA, LLC | 6 | $115 |
| Akebia Therapeutics Inc | 7 | $103 |
| Kyowa Kirin, Inc. | 4 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| Chiesi USA, Inc. | 1 | $35 |
| Amicus Therapeutics, Inc. | 1 | $34 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $15 |
| Cormedix Inc. | 1 | $14 |
How this compares
$11,912 in reported general payments places this provider in the 80th percentile of 125 nephrology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Las Vegas
- Mark VishnepolskyLas Vegas$11.3M
- Raj SinghLas Vegas$9.9M
- Samuel KantorLas Vegas$1M
- Jeffrey RyuLas Vegas$422K
- Lawrence LehrnerLas Vegas$239K
- Richard CottieroLas Vegas$220K
- Kamron SaleemLas Vegas$195K
- Mark AdaimyLas Vegas$142K
- Vincent YangLas Vegas$135K
- Prateek SangheraLas Vegas$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.